The Claim
In children diagnosed with Graves' disease, a baseline FT3/FT4 ratio greater than 0.54 pmol/pmol is associated with a 75% sensitivity and 98% specificity for predicting relapse after antithyroid drug discontinuation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In children with Graves' disease, a baseline FT3/FT4 ratio above 0.54 pmol/pmol correctly identifies 75% of those who will relapse after stopping medication and correctly rules out 98% of those who will not relapse.
See the scientific wording
In children diagnosed with Graves' disease, a baseline FT3/FT4 ratio greater than 0.54 pmol/pmol is associated with a 75% sensitivity and 98% specificity for predicting relapse after antithyroid drug discontinuation, suggesting this ratio may help identify patients at high risk of disease recurrence despite initial remission.
The thyroid gland produces too much T3 compared to T4, and the brain does not properly reduce thyroid activity in response, leading to persistent hormone excess that keeps the immune system attacking the thyroid even after treatment stops.
What the research says
1 studyStudy: The role of the FT3/FT4 ratio in predicting remission and relapse in pediatric Graves’ disease
Doctors found that kids with Graves' disease who have a higher T3-to-T4 blood ratio when first diagnosed are much more likely to get sick again after stopping their medicine — even if they seemed better. This ratio is a very accurate warning sign for relapse.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.